Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 with a highly selective inhibitor for the treatment of prostate cancerKai Yuan(China Pharmaceutical University), Peng Yang(China Pharmaceutical University)Nature CommunicationsMay 25, 202210.1038/s41467-022-30581-4Cited by 18SaveCiteExport RISWatch citationsRelated PapersASO Therapy Targeting STAU2 to Inhibit Pancreatic Ductal Adenocarcinoma Progression and Metastasis by Regulating the PALLD‐Mediated EMT Signaling Pathway|Advanced Science|2025|1